ArticleLung cancer (Amsterdam, Netherlands)2025

Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.

Fangdi Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.